Portfolio company Soleno acquired by Neurocrine

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) announced that its largest holding, Soleno Therapeutics, has agreed to be acquired by Neurocrine Biosciences for $2.9 billion. Soleno, which focuses on rare diseases like Prader-Willi Syndrome, generated $190 million in revenue last year from its lead candidate Vykat XR. Soleno shareholders will receive $53 per share in cash, a 34% premium to the closing price on April 2nd. As of April 1st, Soleno represented 6% of IBT's Net Asset Value. This marks the fourth acquisition within IBT's portfolio in 2026, reflecting a trend of dealmaking in the biotech sector.

Disclaimer*

UK 100

Latest directors dealings